SNGX Soligenix (SNGX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000812796
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
Soligenix insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for SOLIGENIX, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 18, 2022.
- -2.9% median (+28.6% mean) 90-day return after 3 previous buys.
- The trade is 97.6% of the 15,511 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN, CEO AND PRESIDENT SCHABER CHRISTOPHER J bought about $20.0K of SNGX on Oct 2, 2025, the largest insider purchase at the company on our record; 9 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 8,000 shares held after it.
- 1 other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SENIOR VICE PRESIDENT AND CMO Straube Richard bought about $4.0K of SNGX on May 18, 2022; 1 other insider bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 17, 2021.
- -4.8% median (-4.8% mean) 90-day return after 2 previous buys.
- The trade is 22.2% of the 90,095 shares held after it.
- 1 other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN, CEO AND PRESIDENT SCHABER CHRISTOPHER J bought about $8.8K of SNGX on May 18, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 14, 2021.
- The trade is 10.0% of the 70,095 shares held after it.
- 1 other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHAIRMAN, CEO AND PRESIDENT SCHABER CHRISTOPHER J bought about $5.2K of SNGX on Dec 17, 2021; 1 other insider bought within 30 days and 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 14, 2021.
- The trade is 9.1% of the 11,000 shares held after it.
- 1 other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior Vice President and CFO Guarino Jonathan L. bought about $700 of SNGX on Dec 15, 2021; 1 other insider bought within 30 days and 9 funds added in the latest 13F quarter.7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-85.8% year over year
below 88% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-27) · 1.3 days to cover · settled 2026-10-15
below 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SNGX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-78.1%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SNGX: institutional holders (13F)
13F holdings, latest reported quarter
209,507 sh
$83.0K
207,492 sh
$82.2K
157,119 sh
$62.2K
120,267 sh
$47.6K
81,005 sh
$32.1K
Congress trades in SNGX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SNGX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SNGX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$69.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$32.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$13.2K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$7.3K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 2
0 active
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SNGX financials
Revenue growth
-85.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$119.4K
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM SNGX
| FY Dec 2025 | $119.4K |
| FY Dec 2024 | $119.4K |
| FY Dec 2023 | $839.4K |
| FY Dec 2022 | $948.9K |
| FY Dec 2021 | $824.3K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$8.4M |
| FY Dec 2023 | -$8.6M |
| FY Dec 2022 | -$12.7M |
| FY Dec 2021 | -$11.7M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$2.7M |
| Sep 2025 | -$2.9M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity SNGX
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.40x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.93x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -8.51x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -1.17x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -7.91x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-242.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SNGX
| FY Dec 2025 | -235.9% |
| FY Dec 2024 | -250.0% |
| FY Dec 2023 | -23,645% |
| FY Dec 2022 | -334.4% |
| FY Dec 2021 | -173.5% |
| Jun 2026 | -242.1% |
| Mar 2026 | -314.1% |
| Dec 2025 | -235.9% |
| Sep 2025 | -165.6% |
| Jun 2025 | -392.7% |
| Mar 2025 | -400.1% |
| Dec 2024 | -250.0% |
| Sep 2024 | -139.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-126.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SNGX
| FY Dec 2025 | -122.0% |
| FY Dec 2024 | -88.5% |
| FY Dec 2023 | -50.7% |
| FY Dec 2022 | -67.1% |
| FY Dec 2021 | -53.7% |
| Jun 2026 | -126.2% |
| Mar 2026 | -149.6% |
| Dec 2025 | -122.0% |
| Sep 2025 | -102.9% |
| Jun 2025 | -133.0% |
| Mar 2025 | -118.1% |
| Dec 2024 | -88.5% |
| Sep 2024 | -64.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-246.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SNGX
| FY Dec 2025 | -245.4% |
| FY Dec 2024 | -243.2% |
| FY Dec 2023 | -1,093% |
| FY Dec 2022 | -155.3% |
| FY Dec 2021 | -76.2% |
| Jun 2026 | -246.4% |
| Mar 2026 | -315.0% |
| Dec 2025 | -245.4% |
| Sep 2025 | -174.9% |
| Jun 2025 | -403.0% |
| Mar 2025 | -430.8% |
| Dec 2024 | -243.2% |
| Sep 2024 | -134.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$15.3M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2024-12-31 (18 months older than the period end), minus cash 2022-03-31
Enterprise value SNGX
| FY Dec 2025 | -$9.4M |
| FY Dec 2024 | -$16.1M |
| FY Dec 2023 | $104.3M |
| FY Dec 2022 | $4.6B |
| FY Dec 2021 | $6.8B |
| Jun 2026 | -$16.9M |
| Mar 2026 | -$10.7M |
| Dec 2025 | -$9.4M |
| Sep 2025 | -$17.9M |
| Jun 2025 | -$18.6M |
| Mar 2025 | -$16.1M |
| Dec 2024 | -$16.1M |
| Sep 2024 | -$12.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | -124.2% |
| FY Dec 2023 | -6.8% |
| FY Dec 2022 | -0.3% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -227.9% |
| Mar 2025 | -131.5% |
| Dec 2024 | -124.2% |
| Sep 2024 | -88.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SNGX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $119.4K | $839.4K | $948.9K |
| Gross profit | n/a | n/a | $97.3K | $398.1K |
| Operating income | -$11.8M | -$9.4M | -$7.7M | -$14.2M |
| Net income | -$11.1M | -$8.3M | -$6.1M | -$13.8M |
| EPS (diluted) | -2.14 | -4.98 | -12.66 | -4.81 |
| Operating cash flow | -$10.3M | -$8.4M | -$8.6M | -$12.6M |
| Long-term debt | n/a | $0 | $1.0M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
SNGX Stock Sonar score 5/7 axes
Find similar shapesCompareSNGX ranks highest on financial health (99th percentile) and risk and compliance (52nd), and lowest on growth (12th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
